Japan Could Become The First Country To Eradicate HIV

Updated Mar 7, 2025 | 05:00 PM IST

SummaryThe idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Japan Could Become The First Country To Eradicate HIV

Credits: Canva

Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

End of Article

Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Updated Nov 19, 2026 | 09:11 AM IST

SummaryEli Lilly's GLP-1 pill Foundayo will be available for purchase in Canada from January 2027. Health Canada's approval comes just as a recent study observed GLP-1 drugs beat metformin in diabetes prevention.
Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Credit: AI

Canada's regulatory body Health Canada recently approved GLP-1 pill developed by pharmaceutical company Eli Lilly. The weight loss pill offers an alternative to injectable weight-loss and diabetes medications.

The development comes as new study suggests that GLP-1 drugs could be more effective than metformin in preventing Type 2 diabetes and improving blood sugar in people with obesity and prediabetes.

The newly approved drug, Foundayo (orforglipron) is approved for adults with obesity and have at least one related health condition. It is also approved to help manage Type 2 diabetes.

Unlike popular GLP-1 medications like Ozempic and Wegovy, which are administered through injections, Foundayo is taken orally once a day. The company expects the GLP-1 pill to become available in Canadian pharmacies in January 2027.

How Does Foundayo Work?

Also read: Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), which is naturally-occurring hormone released by the gut after eating.

GLP-1 helps regulate blood sugar by stimulating insulin release when glucose levels increase. It also suppresses glucagon, a hormone that raises blood sugar, slows emptying of stomach and targets areas of the brain responsible for appetite. These effects, together, help improve blood sugar control, reduce hunger and support weight loss.

Unlike peptide-based GLP-1 medicines, orforglipron is a small molecule that can be absorbed orally without being broken down by digestive enzymes. It can also be taken without the food and water restrictions that come with some oral GLP-1 medications.

Novo Nordisk’s Rybelsus is already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.

Can GLP-1 Drugs Outperform Metformin?

Also read: New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?

A separate study presented at the American Heart Association's Scientific Sessions 2026 compared GLP-1 medications to metformin in more than 256,000 adults with obesity and prediabetes.

Researchers found that people taking GLP-1 medications were 1.5 times more likely to return to normal blood sugar levels than those taking metformin. They also had a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. GLP-1 users were also at lower risks of heart attacks, strokes and heart failure events.

But the study analysed health records rather than conducting a randomised clinical trial. It also grouped several GLP-1 medicines together, including semaglutide, tirzepatide, liraglutide and dulaglutide. Orforglipron was not among the drugs evaluated.

Study author Vinicius de Sousa Barzon Serra said, "Metformin is still a first-line treatment choice. It is safe, inexpensive and has a long track record. This is less about replacing one medication with another and more about discussing additional options with specific patients."

Side Effects Of GLP-1 Medications

Common side effects of GLP-1 medications include gastrointestinal effects like nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These symptoms are often more noticeable when treatment begins or doses increase.

Although oral medicines offer an alternative to injections, they are not suitable for everyone. It depend on a person's medical history, blood sugar levels, weight and other health conditions.

End of Article

Pennsylvania's Eighth Measles Death Takes US Toll To 11 As Cases Cross 5,700: Who Needs A Booster Shot?

Updated Nov 19, 2026 | 08:19 AM IST

SummaryPennsylvania recently reported its eighth measles-associated death after an individual from Clinton County, who had tested positive for the disease, died. This takes the national measles death toll to 11 as cases cross 5,700.
Pennsylvania's Eighth Measles Death Takes US Toll To 11 As Cases Cross 5,700: Who Needs A Booster Shot?

Credit: AI image

Pennsylvania has reported its eighth measles-associated death of 2026 as the US battles a major outbreak that cost it its measles elimination status.

The news came a day after the Pan American Health Organization (PAHO) announced that the US, Mexico, and Bolivia had lost their measles elimination status. The US had maintained their measles-free status since 2000.

Pennsylvania has recorded around 1,589 confirmed cases across 46 counties, prompting authorities to urge people to check their vaccination status and ensure they are adequately protected. The total number of cases in the US has crossed more than 5,700.

The latest death, confirmed on November 18, involved an unvaccinated resident of Clinton County who had tested positive for measles. Health authorities have not disclosed the individual's age or other relevant details. According to the Pennsylvania Department of Health, the state has also reported 315 hospitalisations linked to the outbreak.

With measles cases spreading everyday, questions about whether adults who received measles vaccines during childhood need another dose have emerged. Health experts believe that most people who have received the recommended two doses of the measles, mumps and rubella (MMR) vaccine do not need a booster.

Who Needs A Booster Measles Vaccine Dose?

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

According to the US Centers for Disease Control and Prevention (CDC), adults born in 1957 or later who do not have evidence of immunity should receive at least one dose of the MMR vaccine. But certain groups are recommended to receive two doses, separated by at least 28 days. These include:

  • Healthcare workers: Those who are exposed to infected patients and could transmit the virus to vulnerable individuals.
  • International travellers: People travelling to countries where measles transmission is occurring.
  • College and university students: Students who may be exposed in crowded environments.
  • People living with immunocompromised individuals: Close contacts of people with weakened immune systems who may be unable to receive live vaccines themselves.
  • People living with HIV: Those who do not have severe immunosuppression and lack of measles immunity.
  • People in outbreak-affected areas: Adults advised to receive a second dose because of increased exposure.

People who have received two documented doses of the MMR vaccine, with the first administered at or after 12 months of age and the doses appropriately spaced, are considered protected for life.

Adults Born Before 1957 Are Considered Immune

Also read: Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

According to the CDC, adults born before 1957 are presumed to have immunity against measles because the virus circulated widely before the vaccine became available in 1963.

However, healthcare workers born before 1957 who do not have a history of previous measles infection should consider receiving two doses of the MMR vaccine.

People vaccinated between 1963 and 1967 with the older inactivated (killed) measles vaccine may also need another dose. This version was later found to be ineffective.

Who Should Avoid The MMR Vaccine?

The MMR vaccine is a live attenuated vaccine, which means it contains weakened forms of the viruses.

Pregnant women and people with severe immune suppression should generally not receive it. Individuals with a history of severe allergic reactions to a previous dose or vaccine component should also seek medical advice.

People who are unsure about their vaccination history, immune status or need for another dose should consult their healthcare provider.

Measles Resurgence In The US

Measles is one of the most contagious infectious diseases. The virus spreads through respiratory droplets and airborne particles. They can remain active in the air for up to two hours after an infected person leaves an area.

Symptoms typically start with fever, cough, runny nose and red, watery eyes, followed by a rash that usually starts on the face and spreads across the body.

Complications can include pneumonia, brain inflammation (encephalitis), permanent disability and death. Infants, young children and people with weakened immune systems are vulnerable. The resurgence has been attributed to declining vaccination coverage.

End of Article

US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Updated Nov 19, 2026 | 01:00 AM IST

SummaryThe CDC has reported elevated rhinovirus/enterovirus and respiratory adenovirus activity across the US, with adenovirus increasing in some regions. It has also flagged Group A strep, whooping cough and walking pneumonia.
US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Credit: iStock

The US Centers for Disease Control and Prevention (CDC) has reported elevated activity of multiple respiratory viruses across the country during the 2026–27 winter season, including rhinovirus/enterovirus and respiratory adenovirus.

While respiratory adenovirus infections are increasing in some regions, the agency says the trends are expected.

In its latest update, the CDC also highlighted Group A strep infections, whooping cough and Mycoplasma pneumoniae, the bacteria responsible for walking pneumonia, as other respiratory illnesses circulating in the US.

Rhinovirus, Adenovirus

Rhinovirus/enterovirus and respiratory adenovirus activity are elevated nationally, according to the CDC. Respiratory adenovirus infections are also increasing in some parts of the country.

Both viruses can cause respiratory symptoms such as cough, fever, nasal congestion and shortness of breath. In severe cases, infections may progress to bronchitis or pneumonia.

Rhinoviruses are among the common causes of the common cold and can also trigger asthma attacks. People with asthma, weakened immune systems or other underlying medical conditions may be at higher risk of severe illness.

Respiratory adenoviruses typically cause mild cold- or flu-like symptoms but can also lead to bronchitis, pneumonia, conjunctivitis (pink eye) and gastrointestinal illness. People with weakened immune systems or existing respiratory or cardiac conditions are at greater risk of severe disease. There are no vaccines available to the public for these infections.

Group A Strep Infections

Reports of Group A strep infections increased in the US as children returned to school this fall, before stabilising, the CDC said.

Most reported infections have involved strep throat or scarlet fever.

However, the bacteria can also cause serious conditions, including streptococcal toxic shock syndrome and necrotising fasciitis, commonly known as flesh-eating disease.

Although most infections are minor, serious illness can occur, particularly among older adults and people with certain underlying health conditions. Healthcare providers can diagnose the infection through testing and prescribe antibiotics when needed.

Walking Pneumonia

Respiratory infections caused by Mycoplasma pneumoniae remain low in most parts of the US, based on emergency department visits and positive test results.

The bacteria commonly cause tracheobronchitis, often described as chest colds, but can also lead to walking pneumonia. People of all ages can get infected, although school-aged children and young adults are most commonly affected.

Most mild infections resolve without medication, while healthcare providers may prescribe antibiotics for pneumonia.

Whooping Cough

Whooping cough, or pertussis, continues to circulate at lower levels compared with post-pandemic peaks, according to the CDC.

The highly contagious respiratory infection is caused by the bacterium Bordetella pertussis and can spread easily from person to person.

Babies younger than one year are at the highest risk of severe disease and complications. Vaccination is the best way to prevent complications, and healthcare providers generally treat the infection with antibiotics.

How To Prevent Respiratory Infections

The CDC recommends basic precautions to reduce the spread of respiratory viruses and bacteria, including:

  • Washing hands regularly
  • Cleaning frequently touched surfaces
  • Covering coughs and sneezes
  • Staying home when sick
  • Taking steps to improve indoor air quality.
People with respiratory symptoms such as fever, cough or shortness of breath should take precautions to avoid spreading infections to others. Severe symptoms, particularly difficulty breathing, warrant medical attention.

End of Article